- Home
- ACB vs BWAY Comparison
ACB vs BWAY Comparison
Compare ACB & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- BWAY
- Stock Information
- Founded
- ACB 2013
- BWAY 2003
- Country
- ACB Canada
- BWAY Israel
- Employees
- ACB N/A
- BWAY N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- BWAY Medical/Dental Instruments
- Sector
- ACB Health Care
- BWAY Health Care
- Exchange
- ACB Nasdaq
- BWAY Nasdaq
- Market Cap
- ACB 256.5M
- BWAY 245.2M
- IPO Year
- ACB N/A
- BWAY 2019
- Fundamental
- Price
- ACB $4.81
- BWAY $11.79
- Analyst Decision
- ACB
- BWAY Strong Buy
- Analyst Count
- ACB 0
- BWAY 2
- Target Price
- ACB N/A
- BWAY $14.25
- AVG Volume (30 Days)
- ACB 1.1M
- BWAY 56.5K
- Earning Date
- ACB 08-06-2025
- BWAY 08-05-2025
- Dividend Yield
- ACB N/A
- BWAY N/A
- EPS Growth
- ACB N/A
- BWAY N/A
- EPS
- ACB 0.03
- BWAY 0.08
- Revenue
- ACB $238,837,444.00
- BWAY $43,457,000.00
- Revenue This Year
- ACB $12.22
- BWAY $351.53
- Revenue Next Year
- ACB $7.36
- BWAY $21.84
- P/E Ratio
- ACB $167.14
- BWAY $57.82
- Revenue Growth
- ACB 27.32
- BWAY 26.86
- 52 Week Low
- ACB $3.42
- BWAY $5.98
- 52 Week High
- ACB $7.20
- BWAY $13.66
- Technical
- Relative Strength Index (RSI)
- ACB 52.50
- BWAY 47.14
- Support Level
- ACB $4.42
- BWAY $11.54
- Resistance Level
- ACB $5.10
- BWAY $12.95
- Average True Range (ATR)
- ACB 0.19
- BWAY 0.54
- MACD
- ACB 0.07
- BWAY -0.17
- Stochastic Oscillator
- ACB 59.15
- BWAY 14.39
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.